Abstract. In Alzheimer´s disease (AD), persistent microglial activation as sign of chronic neuroinflammation contributes to disease progression. Our study aimed to in vivo visualize and quantify microglial activation in 13-to 15-month-old AD mice using [
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Immunostaining revealed the presence of activated microglia clustered around amyloid plaques in the cortex of 12.5-month-old Tg mice as compared with Wt mice, which was more prominent after the wash-out period at the age of 15 months (Fig. 1C) .
Discussion. In the attempt to non-invasively quantify Aß-mediated microglial activation and its therapy-induced modulation in APP/PS1 mice by [ 11 C]-(R)-PK11195 and µPET, we did not observe any statistically significant genotype-or treatment-dependent differences in radiotracer DV at the age of 13-14 months, although immunohistochemistry verified substantial microglial activation in Tg mice at the age of 12.5 months. Venneti et al. (2009) found increased microglial activation in APP/PS1 mice as assessed by immunostaining (Iba-1) and [ 11 C]-(R)-PK11195 PET, only at older age (16-19 months) but not at younger age (13-16 months) . Together with the current study, these data may indicate that at earlier Alzheimer's disease stages, the number of activated microglia is below the limit of detection by After discontinuation of pioglitazone, we detected significantly higher radiotracer DV in 15-monthold Tg mice. Immunohistochemical analysis demonstrated characteristic microglial activation around Aß depositions in the cortex of APP/PS1 mice at this stage, which was more pronounced than in the cortex of 12.5-month-old Tg mice. This finding may indicate natural disease progression or "rebound" activation of microglia after treatment discontinuation.
Taken together, our data suggest that [ 11 C]-(R)-PK11195 µPET is able to assess microglial activation in AD mice only when a certain threshold of activation is reached. Therefore, with the given limitations of the radiopharmaceutical, subtle differences in microglial activation may be missed by this imaging method. Newly developed TSPO-targeted radiotracers with an improved target-tobackground ratio may be able to detect activated microglia at earlier disease stages.
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Supplementary Introduction
Alzheimer's disease (AD) is the most common cause of dementia in elderly people. The disease is characterized by extracellular aggregation of amyloid β (Aβ) in the brain and intracellular aggregation of the tau protein resulting in Aß plaques and neurofibrillary tangles, respectively (Bettens et al., 2010; Bird; Castellani et al., 2010; Van Broeck et al., 2007) . The exact mechanism of how these AD hallmarks cause damage to neuronal cells is still unclear, but one of the most compelling theories is the contribution of activated microglia to AD pathogenesis.
Microglial cells represent the native immune system of the brain and are the first line of defense against brain injury. Under physiological conditions, they reside in a resting state, continuously surveying their environment with motile processes. Upon neuronal injury microglial activation occurs, changing the behavior of the cells from patrolling to shielding.
They migrate towards the injured site where they proliferate and secrete proinflammatory molecules, such as cytokines and reactive oxygen/nitrogen species, resulting in neuronal toxicity (Kofler and Wiley, 2011) . In the AD brain, activated microglia are found in the direct vicinity of Aβ plaques (D'Andrea et al., 2004; Itagaki et al., 1989) . Initially, they take on a neuroprotective role by releasing amyloid-degrading enzymes for the clearance of amyloid fibrils in the early stages of the disease. As the disease progresses, however, these neuroprotective clearing mechanisms are insufficient or too slow to counteract the deposition of Aβ in the AD brain, but the production of the neurotoxic pro-inflammatory molecules is preserved, maintaining chronic neuroinflammation and resulting in neurodegeneration (Cameron and Landreth, 2010; Combs, 2009; Rogers et al., 2002; Sastre et al., 2006) .
The nuclear peroxisome proliferator-activated receptor γ (PPAR-γ) is involved in the inflammatory response of activated microglia. Through transcriptional deactivation, PPAR-γ agonists are able to suppress this response by inhibiting gene expression of pro-inflammatory molecules originating from the activated microglia. Therefore, several PPAR-γ agonists have been studied as a possible therapeutic intervention for neuroinflammation in AD Landreth et al., 2008) .
The peripheral benzodiazepine receptor (PBR) derives its name from its function as a binding site for benzodiazepines and due to its high level of expression in peripheral organs.
Additional research, however, found the receptor expressed all over the body, including in the brain and it was renamed translocator protein-18 kDa (TSPO) (Papadopoulos et al., 2006) .
The expression of TSPO is low in the healthy brain parenchyma but strongly upregulated in activated microglia as shown in both patient and animal studies. Therefore, the expression of TSPO is a marker of choice to study the extent and role of neuroinflammation in several neurological disorders with the use of radiolabeled TSPO-targeted compounds (Cagnin et al., 2007; Venneti et al., 2009b; Winkeler et al., 2010) .
propyl]-3-isoquinolinecarboxamide) binds with high affinity and selectivity to TSPO, as shown in early in vitro and in vivo studies using tritiated PK11195 (Le Fur et al., 1983a; 1983b (Chauveau et al., 2009; Doorduin et al., 2009) .
In this study, we investigated neuroinflammation and cerebral glucose metabolism in APP/PS1 transgenic (Tg) mice, an animal model for AD. Through mutations, these mice 3 overexpress both the Aβ precursor protein (APP) and presenilin 1 (PS1) gene, causing rapid development of Aβ plaques clustered by activated microglia together with the exhibition of behavioral deficits (Garcia-Alloza et al., 2006; Gordon et al., 2002; Yan et al., 2009 ).
Additionally, we evaluated anti-inflammatory treatment with the PPAR-γ agonist pioglitazone, a pharmaceutical drug used for the treatment of diabetes mellitus type 2. The effect of this treatment in both Tg and wild-type (Wt) mice as well as in vivo differences in microglial activation between the two groups were assessed with µPET imaging using 
Supplementary Methods

Animals and experimental procedures
13-month-old female Hu/moAPP Swe /huPSEN1 ΔE9 Tg (n = 7) and control Wt (n = 8) mice on a B6C3 background (Clinical Neurosciences Unit, University of Bonn, Germany) were used in this study. A drop-out of both Tg (n = 4) and Wt (n = 3) mice occurred during the study due to advanced age, and they were replaced by same aged additional animals. All animal procedures were carried out in accordance with the German Laws for Animal Protection and approved by the local animal care committee and governmental authorities.
Prior to imaging, mice were anesthetized with 3% isoflurane (Baxter GmbH, Unterschleissheim, Germany) in nitrous oxide/oxygen (60%/40%) in a small induction chamber and maintained with 1 to 2% isoflurane on a heated (37°C) pad with anesthesia system (Medres GmbH, Cologne, Germany). The amount of delivered anesthesia was monitored and maintained constant manually through observation of the respiratory rate. To facilitate tracer injection, a tail vein catheter was placed by inserting a 32-gauge needle (TSH Laboratory, Japan) connected to a polyethylene tube (Smiths Medical International Ltd, Kent, UK) with an inner diameter of 0.28 mm into the tail vein at a slight angle. Proper placement of the catheter was verified when blood backflow was observed in the tube. A small volume of a heparin-sodium solution (25000 I.E./5 ml, Ratiopharm GmbH, Ulm, Germany) was injected to flush the catheter in order to prevent the blood from clotting and the needle was fixed in the tail using a hypoallergenic adhesive (Leukosilk, BSN medical GmbH, Hamburg, Germany). A special multimodal animal carrier (Medres GmbH, Cologne, Germany) was used for µPET imaging, allowing two mice to be imaged simultaneously for each scan, thereby reducing the number of experiments and increasing the efficacy of tracer usage, especially for tracers with a short half-life, like [ 11 C]-(R)-PK11195. The carrier was equipped with a nose cone to maintain anesthesia, a tooth bar to fix the animal and a rectal temperature probe connected to an automatically controlled heating system (Medres GmbH, Cologne, Germany) to maintain the body temperature constant.
After baseline imaging (13 months), all animals were treated on a daily basis for 5 weeks by feeding them ad libitum standard chow complemented with 240 p.p.m pioglitazone (Actos™, Takeda Pharmaceuticals Co. Ltd., Osaka, Japan). During this period, animals were housed separately to allow observation of drug intake by weighing the animal and the residual food pellets daily. Based upon average daily food intake of 5 g of chow per mouse, the final dose of pioglitazone was calculated to 40 mg/kg/day. To assess the anti-inflammatory effect of the treatment, the imaging protocol was repeated after the treatment period (14 months) as well as after a subsequent 5-week wash-out period (15 months).
Radiochemistry
Radiosynthesis of [ 11 C]-(R)-PK11195 was accomplished by N-methylation using the method of Camsonne et al. (1984) with slight modifications. (HPLC, Nucleosil 100 C18; Macherey-Nagel, Düren, Germany, 10x250 mm, flow: 3 ml/min).
The product fraction was diluted with 50 ml of water, [ 11 C]-(R)-PK11195 fixed on a C18 SPE Cartridge (strata-X, Phenomenex, Torrance, CA, USA) and eluted with 0.7 ml of EtOH. The final formulation for injection consisted of 10% isotonic EtOH solution. Radiochemical purity 6 was > 99%. The specific activity was in the range of 0.5 to 2.2 Ci/µmol. The radiochemical yield amounted to 8 to 15% (decay corrected). [ 18 F]FDG was produced as described earlier by Hamacher et al. (1986) .
µPET and µMRI imaging
Before tracer injection, the animal carrier with the anesthetized and fixed mice was positioned in a high-resolution (spatial resolution ~1.5 mm) µPET Focus 220 scanner (Concorde Microsystems, Inc., Knoxville, TN, USA) with the mice brains placed close to the center of the field of view.
Dynamic µPET imaging was performed on two different days of the same week at baseline, after a 5-week anti-inflammatory treatment and after a 5-week wash-out period followed by a 10 min transmission scan using a Cobalt-57 source to correct for attenuation.
µPET data analysis
Data reconstruction
Emission data were histogrammed in 21 time frames (12x30, 3x60, 3x120, 3x240 s) for From the co-registered [ 18 F]FDG µPET dynamic images, IFs were derived from the liver TAC as described previously (Yu et al., 2009 ). To extract the liver TAC, a large VOI containing the liver was drawn manually onto the images. The TAC was calculated as the average TAC from the 15 voxels within the VOI that contained the highest activity during the first three minutes after tracer injection. The IF was then given by the liver TAC divided by the recovery coefficient (0.58) that accounts for the liver partial-volume effect (Green et al., 1998; Yu et al., 2009 (Sokoloff, 1977) .
Immunohistochemistry
Before the start of the treatment period (12.5 months) as well as after off treatment imaging (15 months), representative Tg and Wt mice were anesthetized and perfused transcardially with phosphate buffered saline (PBS). After perfusion, the animals were killed and their brains were quickly removed and fixed in 4% paraformaldehyde (PFA). Brains were sagitally cut into free-floating 40 µm thick sections using a vibratome (Leica, Wetzlar, Germany). For immunostaining, the selected sections were first fixed (15 min in 50% methanol), washed (3 times 5 min in PBS) and blocked (30 min in PBS, 0.1% Triton X100, 3% bovine serum albumin blocking buffer). Next, the sections were incubated overnight at 
Statistical Analysis
All statistical analyses were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA Mean values obtained between the two groups were statistically analyzed using a two-tailed independent Student's t test. Posthoc Bonferroni correction was applied after every test to account for multiple testing. Statistical significance was set at a 5% level (p < 0.05). 
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Quantification of [ 11 C]-(R)-PK11195 and [ 18 F]FDG kinetic parameters using an image-derived IF
[ 11 C]-(R)-PK11195 distribution volume and [ 18 F]FDG metabolism
µPET imaging using Fig. 3B ).
Immunofluorescent staining
The extent of activated microglia and Aβ depositions was assessed with the use of antibodies against CD11b and Aβ, respectively, and determined in the cortex of 12.5-and 15-month-old Tg and Wt mice (Fig. 1C) . In Tg mice, immunostaining revealed the presence of activated microglia in the vicinity of amyloid plaques at 12.5 months and, more prominently, at 15 months. On the contrary, in Wt mice no amyloid plaques were present at any time point, and hardly any CD11b-positive cells were detectable, demonstrating an increased microglial activation and plaque formation in Tg mice compared with Wt mice.
Supplementary Discussion
In the attempt to non-invasively quantify Aß-mediated microglial activation and its therapy-induced modulation in an AD mouse model using [ 11 C]-(R)-PK11195 and µPET, we observed statistically significant higher radiotracer DV in 15-month-old Tg mice compared with control mice after discontinuation of the therapeutic modulator pioglitazone.
Immunohistochemical analysis of the cortex of Tg mice demonstrated characteristic microglial activation around Aß deposition at this stage. There was no evidence of microglial activation in Tg mice at the earlier age of 13-14 months as assessed by statistical analysis of AD is characterized by the deposition of insoluble Aβ plaques, which activate microglia to guide amyloid clearance. However, upon continuous activation, microglia secrete neurotoxic pro-inflammatory molecules that cause direct neuronal damage and induce a vicious cycle of chronic neuroinflammatory-mediated cell death (Glass et al., 2010) . Noninvasive molecular imaging as well as the creation of Tg mouse models by introducing mutations in APP and/or PS1 genes play a relevant role in improving our understanding of the temporal disease dynamics of AD in humans (Waerzeggers et al., 2010) . Several in vitro and in vivo staining agents (e.g. Thioflavine-S, Bussiere et al., 2004) (Bacskai et al., 2001; Rinne et al., 2010) .
In this study, we hypothesized that APP/PS1 mice have an increased level of activated microglia and thus neuroinflammation compared with control mice. Therefore, we Although Ruan et al. (2009) Follow-up measurements in our study were performed 5 and 10 weeks after the baseline study and were combined with the idea that microglial activation could be modulated by a PPAR-γ agonist. PPAR-γ is a nuclear receptor that plays an important role in inflammatory processes. Agonists that bind and activate PPAR-γ, suppress inflammation by inhibiting the expression of pro-inflammatory molecules at the transcriptional level. Therefore, we expected to detect a therapy-induced reduction in comparison to the baseline level of activated microglia in Tg mice after anti-inflammatory treatment with the PPAR-γ agonist pioglitazone. Lim et al. (2000) and Heneka et al. (2005) used in addition the PPAR-γ agonist ibuprofen in another Tg mouse model for AD, and immunohistochemistry showed a significant decrease of microglial activation in the ibuprofen-treated mice. We did not include an additional ibuprofen treated control group since the previous data from Heneka et al. (2005) Immunohistochemistry obtained from representative animals shortly after off-treatment imaging confirmed the presence of activated microglia clustered around Aβ plaques in the cortex of Tg mice, which was more pronounced than in the cortex of 12.5-month-old Tg mice. The presence of activated microglia has already been shown in the human AD brain (Itagaki et al., 1989) and in a mouse model of AD (Frautschy et al., 1998) and has been confirmed by other research groups in more recent studies (Bolmont et al., 2008; MeyerLuehmann et al., 2008; Rodriguez et al., 2010) . Our µPET and immunohistochemistry results in the 15 months age group suggest the occurrence of neuroinflammation in the brains of APP/PS1 mice. The fact that we were not able to detect any statistical significant differences at earlier disease stages may as well be due to the fact that [ 11 C]-(R)-PK11195 has a high level of non-specific binding, a poor signal-to-noise ratio and relatively low sensitivity, all complicating PET quantification. Newly developed TSPO-targeted radiotracers with an improved target-to-background ratio may be able to detect activated microglia even at this early stage of disease progression (Chauveau et al., 2008) .
In addition to non-invasive quantification of microglial activation, we aimed to investigate the correlation between neuroinflammation and neuronal function as determined by conditions between AD and control mice, supporting our results. Only after inflicting neuronal damage to the locus coeruleus, a significant difference between the two animal groups could be observed. A possible explanation for preserved cerebral glucose metabolism in Tg mice compared with Wt mice may be the lack of a global neuronal loss in the brains of APP and APP/PS1 mouse models, despite their extensive amyloid plaque pathology at the age of investigation (Irizarry et al., 1997; Takeuchi et al., 2000) .
In conclusion, our multi-tracer µPET study in APP Swe /PS1 dE9 mice and their littermate controls did not depict the hypothesized differences in 
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